Navigation Links
FDA approves PleximmuneTM for personalized prediction of transplant rejection in children
Date:9/11/2014

PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM, a blood test from the Pittsburgh-based biotech company Plexision. This test predicts acute cellular rejection of transplanted livers and intestines in children. PleximmuneTM is a first-in-class test to determine a personalized rejection-risk index using cell-based technology.

The PleximmuneTM blood test predicts acute cellular rejection with an overall accuracy approaching or exceeding 80 percent in the 60-day period following the test. Test performance has been established in research blood samples from more than 200 children who received liver or intestine transplantation at the Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center.

PleximmuneTM fulfills an unmet need to measure rejection-risk non-invasively after liver or intestine transplantation. Half of all transplant recipients experience acute cellular rejection over their lifetimes. Repeated episodes lead to gradual loss of organ function. Therefore, estimating the risk of rejection is an essential component of recipient care. Rejection-risk is currently estimated with clinical information including blood tests, which can measure organ function; however, rejection is not always accompanied by abnormal blood tests. Additionally, blood tests may provide incomplete information about organ function.

Plexision (www.plexision.com) develops personalized test systems for transplantation, immunological disorders and drug development using patented technology licensed exclusively to Plexision by the University of Pittsburgh. PleximmuneTM is designated a Humanitarian Use Device by the FDA's Office for Orphan Products and has been approved under the Humanitarian Device Exemption program of the FDA for rare disease populations. The test is performed on samples shipped to Plexision's CLIA-certified reference laboratory in Pittsburgh. Plexision's Chief Executive Officer, Ashok Reddy, says,  "Understanding the developing immune systems of children who receive lifelong antirejection medicines after transplantation can be challenging. We see such challenges of unique patient populations as opportunities for personalized diagnostics."

To learn more about Plexision and its products, please visit www.plexision.com, email info@plexision.com, call 412-224-2507 or fax a request to 412-224-2776.

Media Contact: Ashok Reddy, PLEXISION, INC, 412 224 2507, ashok@plexision.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE PLEXISION, INC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
2. FDA Approves NDA Supported By MedAvante Central Ratings
3. Cardinal Health Board Of Directors Approves Cash Dividend; Authorizes New $750 Million Share Repurchase Program
4. FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
5. Specialty Pharmacy Certification Board (SPCB) Approves Content for Certified Specialty Pharmacist (CSP) Certification Exam
6. FDA APPROVES APTIMA HPV ASSAY FOR USE ON HOLOGICS PANTHER SYSTEM
7. FDA Approves Epaned, a Liquid Form of Enalapril for Children and Adults
8. FDA approves drug tested by Scottsdale Healthcare and TGen
9. FDA Approves Aptima HPV 16 18/45 Genotype Assay for Use on Hologics Panther System
10. PMDA Approves Jarvik 2000 Heart in Japan
11. Cardinal Health Board of Directors Approves Quarterly Dividend, Authorizes Increase to Share Repurchase Program, Announces Board Leadership Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):